April 15 (Reuters) - Intellipharmaceutics International Inc
I.TO
* Intellipharmaceutics announces first quarter 2016 results
* Q1 loss per share $0.09
* Q1 earnings per share view $-0.10 -- Thomson Reuters
I/B/E/S
* Plan to file new drug application for rexista oxycodone xr
within three months on basis that no phase iii studies required
* Progress on rexista oxycodone xr continues, nda user fee
waiver request filed
Source text for Eikon: ID:nGNXMQLPVa
Further company coverage: I.TO
(Bengaluru Newsroom: +1-646-223-8780)